# NCT06100874 (NCT06100874)

> A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06100874
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Adrienne G. Waks
- Conditions: Her 2 Positive Breast Cancer; Breast Cancer Female; Breast Cancer Metastatic
- Interventions: Sacituzumab Govitecan; Trastuzumab; Trastuzumab and Hyaluronidase-oysk
- Enrollment: 28
- Primary outcome: Overall Response Rate (ORR)

## Commentary we found

- X threads: 30
- YouTube: 4
- X videos: 2
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct06100874

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06100874", "email": "<work email>"}; the inbox owner confirms by the emailed link.